All Stories

  1. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
  2. A Phase II, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients
  3. Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis
  4. Development of a Set of Lupus‐Specific Ambulatory Care Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study
  5. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
  6. Case 31-2019: A 45-Year-Old Woman with Headache and Somnolence
  7. Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed Pseudomonas aeruginosa Clonal Complex 446 in an Academic Medical Center
  8. Reply to Singh
  9. Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals
  10. 1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis
  11. 2453. Prolonged Local Epidemic of an XDR P. aeruginosa Subclade of High-Risk Clonal Complex 298
  12. 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
  13. 269. Epidemiology and Outcomes of Invasive Aspergillosis (IA) Among Pediatric Immunocompromised Patients: A 12-Year, Single-Center Experience
  14. Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells
  15. Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease: Case Series and Systematic Review of the Literature
  16. Herpes Zoster Subunit Vaccination for Renal Transplant Recipients
  17. Draft Genome Sequence of Pseudomonas aeruginosa Strain BWH047, a Sequence Type 235 Multidrug-Resistant Clinical Isolate Expressing High Levels of Colistin Resistance
  18. Reply to Aronson et al
  19. Five-Year Follow-up after Face Transplantation
  20. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
  21. Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?
  22. Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation
  23. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
  24. Authors’ Response
  25. 1140. GATA2 Mutations Are Frequently Identified Among Patients With Myeloid Malignancies Who Develop Invasive Aspergillosis
  26. 1557. Acyclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients
  27. 1564. Lower Rates of Epstein–Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
  28. 1576. Risk of Clinical Tuberculosis (TB) Among Patients with Latent TB Infection (LTBI) Who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT)
  29. 1715. A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Immunocompromised (IC) Patients With Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO)
  30. 1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
  31. 358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
  32. 408. Invasive Fungal Petrositis and Carotiditis (IFPAC) Syndrome in Immunocompromised Hosts: An Unrecognized, Often Catastrophic Invasive Fungal Disease (IFD)
  33. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
  34. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
  35. Isavuconazole for treatment of rare invasive fungal diseases
  36. Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib
  37. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection
  38. Case 5-2018: A Man with Confusion after Stem-Cell Transplantation
  39. NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation
  40. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation
  41. Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis
  42. Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation
  43. Optical modeling of black silicon using an effective medium/multi-layer approach
  44. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
  45. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species
  46. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer
  47. Letermovir Prophylaxis for Cytomegalovirus
  48. Risk of hepatitis B virus reactivation in patients treated with ibrutinib
  49. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation
  50. Eponychial lesions following bilateral upper extremity vascular composite allotransplantation: a case report
  51. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
  52. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana‐Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline
  53. Seasonal Variability Precipitating Hand Transplant Rejection?
  54. Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid
  55. Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation
  56. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy
  57. Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart
  58. dasatinib increases risk of cytomegalovirus reactivation when used after BMT
  59. mucositis had little impact on isavuconazole absorption
  60. Warm autoimmune hemolytic anemia can develop in patients with babesiosis
  61. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana‐Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline
  62. IV zanamivir was as effective as oral oseltamivir in patients with severe influenza
  63. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications
  64. Face Transplantation in a Highly Sensitized Recipient
  65. Introducing the Wiley Transplant Peer Review Network
  66. The VITAL study: case control studies are hypothesis-generating – Authors' reply
  67. Introducing the Wiley Transplant Peer Review Network
  68. Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study
  69. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
  70. Introducing The Wiley Transplant Peer Review Network
  71. Face Transplantation in a Highly Sensitized Recipient
  72. Guillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation
  73. Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia
  74. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors
  75. Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer
  76. In Vitro Volatile Metabolite Signatures of Common Pathogenic Fusarium Species
  77. Norovirus Infection in Transplantation: Prolonged and Morbid Diarrhea
  78. Scedosporium and lomentospora have unique in vitro VOC profiles
  79. Safety of Foscarnet (FOS) Treatment for Human Herpesviruses (HHV) in a Contemporary Cohort of Immunocompromised Patients
  80. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia
  81. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors
  82. Cerebrospinal fluidCoccidioidesantigen testing in the diagnosis and management of central nervous system coccidioidomycosis
  83. Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience
  84. Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis
  85. Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation
  86. BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation
  87. Risk factors for invasive fungal disease in heart transplant recipients
  88. Decreasing Incidence of Candidemia Without Routine Systemic Antifungal Prophylaxis
  89. Utility of Sentinel Flaps in Assessing Facial Allograft Rejection
  90. A Breath Fungal Secondary Metabolite Signature to Diagnose Invasive Aspergillosis
  91. Reply to "Insufficient Demonstration of Long-Term Stability of Aspergillus Galactomannan"
  92. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
  93. Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation
  94. Serologic Response to Hepatitis B Vaccination Among Lung Transplantation Candidates
  95. Triple opportunistic pulmonary cavitary disease after cord blood transplantation
  96. Clinical characteristics and outcomes of clostridial bacteraemia in cancer patients
  97. The polyomavirus puzzle: is host immune response beneficial in controlling BK virus after adult hematopoietic cell transplantion?
  98. The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant
  99. Green Herring Syndrome: Bacterial Infection in Patients With Mucormycosis Cavitary Lung Disease
  100. Long-Term Stability at -20 C of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens
  101. BK Virus Disease after Allogeneic Stem Cell Transplantation: A Cohort Analysis
  102. Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
  103. Adjunctive management of central line-associated bloodstream infections with 70% ethanol-lock therapy
  104. Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients
  105. disseminated mucormycosis treated successfully with isavuconazole
  106. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation
  107. Cost analysis of dental services needed before hematopoietic cell transplantation
  108. Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006
  109. Ask, Don't Tell — Mobile Phones to Improve HIV Care
  110. Bradyrhizobium enterica in Cord Colitis Syndrome
  111. Incidence and risk factors for herpes zoster following heart transplantation
  112. CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
  113. Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
  114. Sequence-Based Discovery ofBradyrhizobium entericain Cord Colitis Syndrome
  115. Postoperative Antibacterial Prophylaxis for the Prevention of Infectious Complications Associated With Tube Thoracostomy in Patients Undergoing Elective General Thoracic Surgery
  116. Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis
  117. Fatal adenovirus encephalomyeloradiculitis in an umbilical cord stem cell transplant recipient
  118. Vascularized composite tissue allotransplantation - state of the art
  119. Neutropenia Associated With Prolonged Daptomycin Use: Table 1.
  120. Infections Following Facial Composite Tissue Allotransplantation-Single Center Experience and Review of the Literature
  121. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis
  122. Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis
  123. InvasiveMycoleptodiscusfungal cellulitis and myositis
  124. Safety of Posaconazole and Sirolimus Coadministration in Allogeneic Hematopoietic Stem Cell Transplants
  125. A Targeted Peritransplant Antifungal Strategy for the Prevention of Invasive Fungal Disease After Lung Transplantation
  126. Respiratory Virus Detection in Immunocompromised Patients with FilmArray Respiratory Panel Compared to Conventional Methods
  127. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study
  128. Infectious Disease Board Review Questions
  129. Post-diagnostic kinetics of the (1 → 3)-β-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia
  130. Three Patients with Full Facial Transplantation
  131. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients
  132. Serum Galactomannan and (1->3)- -D-Glucan Assays for Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia
  133. Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed?
  134. How Do We Manage Oral Infections in Allogeneic Stem Cell Transplantation and Other Severely Immunocompromised Patients?
  135. Cord Colitis Syndrome in Cord-Blood Stem-Cell Transplantation
  136. Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation
  137. Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009
  138. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
  139. Pandemic H1N1 Influenza Infection in Adult Transplant Recipients
  140. Timeline of Infections after Hematopoietic Stem Cell Transplant
  141. Immune Reconstitution after Myeloablative Stem Cell Transplant
  142. Elevated Serum Beta-d-Glucan Levels in Immunocompromised Children with Clinical Suspicion for Pneumocystis jirovecii Pneumonia
  143. Molecular Methods To Improve Diagnosis and Identification of Mucormycosis: Fig. 1.
  144. HIV-1 and 2009 H1N1 Influenza A in Adults
  145. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
  146. Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
  147. Cerebral phaeohyphomycosis caused by Bipolaris spicifera after heart transplantation
  148. Infectious Complications Associated with Immunomodulating Biologic Agents
  149. Gordonia bronchialis Bacteremia and Pleural Infection: Case Report and Review of the Literature
  150. Invasive Fungal Disease after Remote Inoculation in Transplant Recipients
  151. Xenotropic Murine Leukemia Virus–Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions
  152. Fonsecaea monophoracerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review
  153. Aspergillus DNA contamination in blood collection tubes
  154. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients
  155. Invasive fungal disease in patients treated for newly diagnosed acute leukemia
  156. Infectious Complications Associated with Immunomodulating Biologic Agents
  157. Disseminated dermatophytosis in a patient with hereditary hemochromatosis and hepatic cirrhosis: case report and review of the literature
  158. Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis
  159. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
  160. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis
  161. Infectious Granulomatous Dermatitis Associated With Rothia mucilaginosa Bacteremia: A Case Report
  162. Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis
  163. Transplant infectious disease as a subspecialty: does outlining how we train define who we are?
  164. Diagnostic Performance of the (1→3)‐β‐d‐Glucan Assay for Invasive Fungal Disease
  165. Diagnostic Efficacy and Safety of Computed Tomography-Guided Transthoracic Needle Biopsy in Patients with Hematologic Malignancies
  166. DisseminatedGeotrichum candiduminfection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature
  167. Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation
  168. Strongyloideshyperinfection syndrome and transplantation: a preventable, frequently fatal infection
  169. Positively false
  170. Role of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosis
  171. Human herpesvirus 6 encephalitis
  172. Recovery of Herbaspirillum Species from Persons with Cystic Fibrosis
  173. POST-TRANSPLANT ACUTE LIMBIC ENCEPHALITIS: CLINICAL FEATURES AND RELATIONSHIP TO HHV6
  174. Persistent and Relapsing Babesiosis in Immunocompromised Patients
  175. chapter reviewing key infectious diseases after hematopoietic-cell transplantation
  176. Management of Oral Infections in Cancer Patients
  177. Posaconazole for Invasive Aspergillosis?
  178. Post-transplant acute limbic encephalitis: Clinical features and relationship to HHV6
  179. (1→3)β-d-Glucan Assay Positivity in Patients with Pneumocystis (carinii) jiroveci Pneumonia
  180. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study
  181. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
  182. Torsades de pointes associated with voriconazole use
  183. Reactivity of (1→3)-β-d-Glucan Assay with Commonly Used Intravenous Antimicrobials
  184. The persistent challenges of bacterial infections in the transplant recipient
  185. Treatment of Cavitary Pulmonary Zygomycosis With Surgical Resection and Posaconazole
  186. Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
  187. Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation
  188. Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation
  189. Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis
  190. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy
  191. Lyme Meningoradiculitis and Myositis after Allogeneic Hematopoietic Stem Cell Transplantation
  192. Treatment of Human Disseminated Strongyloidiasis with a Parenteral Veterinary Formulation of Ivermectin
  193. Myiasis Due toDermatobia hominis(Human Botfly)
  194. Caspofungin versus Liposomal Amphotericin B for Empirical Therapy
  195. Principles of antimicrobial therapy in the transplant patient
  196. Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants
  197. Disseminated Trichosporonosis Caused by Trichosporon loubieri
  198. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
  199. Antifungal use in HIV infection
  200. patient with neurosyphilis presented with temporal lobe syndrome